BioSpace News Archive

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced upcoming data presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held May 11-14, 2021, in a virtual format.

Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system disorders, announced that it will report its financial results for the first quarter of 2021 on Monday, May 10, 2021 before the opening of the U.S. financial markets.

Proceeds to support clinical progress of differentiated anti-CD47 candidate AO-176 for patients with solid tumors and hematologic malignancies

Aravive Inc., a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, announced the Company has dosed the first patient in its Phase 3 trial of AVB-500 in platinum resistant ovarian cancer.

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today the appointment of Henry Rath as chief business officer, and the promotions of Alison O’Neill, M.D. to chief medical officer and Jessica Fees to chief financial officer.

Instil Bio, Inc. received orphan drug designation from the U.S. Food and Drug Administration for the treatment of melanoma stages IIB to IV with its ITIL-168 TIL therapy.

Signature Biologics, LLC., today announced that its research on the immunomodulatory properties of mesenchymal stem cells derived from human umbilical cord (hUC-MSCs) has been published in the Journal of Translational Medicine,

Company will receive up to $5 Million in grant funds from DARPA as part of the agency’s Nucleic Acids On-Demand World-Wide Program to plan for and prevent the next viral pandemic

Peer reviewed data demonstrate synergistic effect of anti-TIGIT antibody, COM902, with PVRIG and PD-1 blockade for the treatment of cancer Phase 1 trial of COM902 monotherapy in patients with advanced malignancies is currently on track to report data in Q4 2021; Initiation of dual combination study for COM701 with COM902 expected as planned in H2 2021

- Under the terms of the research collaboration and exclusive option agreement, the companies will initiate a gene editing research program dedicated to the treatment of two early onset indications with high unmet need, leveraging the GeneRide™ platform -